Long-term Remissions with Gilteritinib in Early Relapse After Allogeneic Stem Cell Transplantation of FLT3/NPM1 Mutated Acute Myeloid Leukemia

Overview

Journal Blood Cell Ther

Date 2024 Sep 12

PMID 39263622

Authors

E Tamellini

M Sorio

A Andreini

C Tecchio

G Nadali

A Bernardelli

I Ferrarini

L Crosera

A Vatteroni

C Simio

F Benedetti

M Krampera

I Tanasi

Affiliations

Soon will be listed here.

Abstract

Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting. Here, we report three patients with FLT3 and NPM1 mutated AML who relapsed early after allo-HSCT and were treated with gilteritinib (associated with donor lymphocyte Infusion in two patients) to achieve long-term remission without a second transplantation.

References

Burchert A . Maintenance therapy for -mutated acute myeloid leukemia. Haematologica. 2021; 106(3):664-670. PMC: 7927878. DOI: 10.3324/haematol.2019.240747. View

Perl A, Martinelli G, Cortes J, Neubauer A, Berman E, Paolini S . Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. N Engl J Med. 2019; 381(18):1728-1740. DOI: 10.1056/NEJMoa1902688. View

Bejanyan N, Weisdorf D, Logan B, Wang H, Devine S, de Lima M . Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2014; 21(3):454-9. PMC: 4329076. DOI: 10.1016/j.bbmt.2014.11.007. View

Burchert A, Bug G, Fritz L, Finke J, Stelljes M, Rollig C . Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020; 38(26):2993-3002. DOI: 10.1200/JCO.19.03345. View

Zhang Z, Hasegawa Y, Hashimoto D, Senjo H, Kikuchi R, Chen X . Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2022; 57(5):775-780. DOI: 10.1038/s41409-022-01619-4. View

Sora F, Chiusolo P, Metafuni E, Bellesi S, Giammarco S, Laurenti L . Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. Leuk Res. 2010; 35(3):422-3. DOI: 10.1016/j.leukres.2010.10.025. View

Perl A, Larson R, Podoltsev N, Strickland S, Wang E, Atallah E . Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022; 139(23):3366-3375. PMC: 9197557. DOI: 10.1182/blood.2021011583. View

Biavasco F, Zeiser R . FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. Int J Hematol. 2022; 116(3):341-350. PMC: 9392688. DOI: 10.1007/s12185-022-03352-6. View

Blackmon A, Aldoss I, Ball B . FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation. Blood Lymphat Cancer. 2022; 12:137-147. PMC: 9464008. DOI: 10.2147/BLCTT.S281252. View

10.

Alotaibi A, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia T, DiNardo C . Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021; 2(2):125-134. PMC: 7935111. DOI: 10.1158/2643-3230.BCD-20-0143. View

11.

Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J . Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020; 21(9):1201-1212. DOI: 10.1016/S1470-2045(20)30455-1. View

12.

Metzelder S, Schroeder T, Finck A, Scholl S, Fey M, Gotze K . High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012; 26(11):2353-9. DOI: 10.1038/leu.2012.105. View

13.

Mathew N, Baumgartner F, Braun L, OSullivan D, Thomas S, Waterhouse M . Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018; 24(3):282-291. PMC: 6029618. DOI: 10.1038/nm.4484. View

14.

Griffin J, Song Y, Yang H, Freimark J, Shah M . Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes. Eur J Haematol. 2021; 107(5):553-565. PMC: 9292256. DOI: 10.1111/ejh.13692. View